
A lyophilized peptide quotation is incomplete if it names only the peptide and vial count. The buyer also needs to know which container and closure are proposed, what storage claim the available data support, and which tests belong to the finished presentation. These are project decisions, not attributes that follow automatically from the word “lyophilized.”
Define the product presentation first
Write down whether the request is for bulk lyophilized powder or a filled vial presentation. If it is a vial, specify the intended fill description, container and closure requirements, pack configuration, label content and destination market. Ask which parts of that description are fixed and which are subject to feasibility review.
A visually intact vial does not establish identity, content or stability. The documentation plan should connect the proposed presentation to agreed analytical acceptance criteria and the relevant batch.
Questions for the packaging file
- What container and closure are proposed, and who approves substitutions?
- Which material contacts the product during storage and shipment?
- What packaging checks and batch identifiers will appear in the release record?
- How will a damaged closure, label discrepancy or temperature excursion be assessed?
- Which party owns the final label wording and destination-market review?
These questions establish the evidence to request; they do not presume that every project needs the same tests. Requirements depend on formulation, intended use and applicable market rules.
Read stability information against the exact configuration
Separate observed data from a proposed shelf life
Ask which material, batch, container and storage conditions generated the available stability data. A statement based on a different package or material grade may not support the presentation being quoted. Record the planned time points, test attributes and responsibility for reviewing results, without turning a preliminary estimate into a guaranteed shelf life.
Keep transport in the discussion
Storage instructions and shipping arrangements should be consistent with the evidence available for the relevant material. Agree what happens if a shipment deviates from those instructions: who receives the information, who assesses the effect, and what evidence is needed before use or release.
ICH Q1A(R2) sets out stability-testing principles for new drug substances and products. Its regulatory scope is pharmaceutical. It can inform questions for a medicinal programme, but it does not assign a universal shelf life to cosmetic or research peptide powders.
What to send with the first RFQ
- Peptide identity or controlled project reference, intended use and market.
- Bulk powder or vial presentation, approximate order scale and pack preference.
- Target specification and any existing stability or packaging information.
- Required release, storage and shipment documents.
Our lyophilized peptide CDMO service covers formulation review, vial presentation and project documentation within an agreed scope. Use the RFQ form to submit the intended presentation and evidence needs.
FAQ
Does freeze-drying alone establish a shelf life?
No. A shelf-life proposal requires stability evidence relevant to the actual material and packaging configuration.
Can a buyer change the vial or closure after a pilot batch?
It can be proposed, but the effect on packaging, testing and available stability evidence needs review before the new configuration is approved.
Is one shipping condition suitable for every lyophilized peptide?
No. The applicable condition belongs in the agreed material specification and should be supported by project-specific evidence.
